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ABSTRACT

ROLE OF VAV2 IN PODOCYTE INFLAMMASOME ACTIVATION AND GLOMERULAR
INJURY DURING HYPERHOMOCYSTEINEMIA

By Sabena M. Conley

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2016

Major Director: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology

Hyperhomocysteinemia (hHcys) is a widely known pathogenic factor in the progression of endstage renal disease (ESRD) and it is also associated with an increased risk for injurious
cardiovascular pathologies during ESRD. HHcys is linked to the formation and activation of the
NOD-like receptor protein 3 (NLRP3) inflammasome, characterized as a critical early mechanism
initiating the inflammatory response. NADPH oxidase (NOX)-derived reactive oxygen species
(ROS) mediate the activation of the NLRP3 inflammasome in podocytes in response to elevated
levels of homocysteine (Hcys) in vitro and in vivo. However, it remains unknown how NLRP3
inflammasome activation is triggered by NOX. The aim of the present study sought to determine
the signaling cascade that triggers glomerular injury and sclerosis during hHcys mediated by Vav2,

XV
a guanine nucleotide exchange factor (GNEF). Using both genetic and pharmacological
interventions of Vav2, we first tested whether this GNEF is involved in hHcys-induced NLRP3
inflammasome activation in podocytes by its role in activation of the Rac-1-NOX complex.
Further, we explored whether pharmacological targeting of Vav2 activation may regulate NLRP3
inflammasome signaling pathway during hHcys-induced glomerular injury. We found that mice
with hHcys (on the FF diet) or oncoVav2 (a constitutively active form of Vav2) transfection in the
kidney exhibited increased colocalization of NLRP3 with apoptosis-associated speck-like protein
(ASC) or caspase-1 and elevated IL-1β levels in glomeruli, indicating the formation and activation
of the NLRP3 inflammasome. This glomerular NLRP3 inflammasome activation was
accompanied by podocyte dysfunction and glomerular injury, even sclerosis. Local transfection of
Vav2 shRNA plasmids significantly attenuated hHcys-induced NLRP3 inflammasome activation,
podocyte injury, and glomerular sclerosis. In cultured podocytes, Hcys treatment and oncoVav2
transfection increased NLRP3 inflammasome formation and activation. This NLRP3 activation
was inhibited by Vav2 shRNA, associated with reduction of Rac-1 activity and ROS production.
Administration of NSC23766, a Rac-1 inhibitor substantially attenuated inflammasome formation,
desmin expression and decreased podocin expression in glomeruli of hHcys mice. These results
suggest that elevated Hcys levels activate Vav2 and thereby increase NOX activity, leading to
ROS production. ROS trigger NLRP3 inflammasome activation, podocyte dysfunction and
glomerular injury. Therefore, the present study defines a novel mechanism underlying hHcysinduced NLRP3 inflammasome activation and its progression to ESRD.

CHAPTER ONE
INTRODUCTION
Hyperhomocysteinemia (hHcys) is recognized as a significant contributor to the
development of glomerular dysfunction; if left untreated eventually, hHcys-associated glomerular
injury can progress into consequent end-stage renal disease (ESRD). It has been reported that the
molecular mechanisms mediating the pathogenic action of hHcys is dependent on nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (NOX), which generates the primary enzymatic
product, superoxide (O2.-). NOX-derived oxidative stress has been associated with the initiation
and progression of glomerular diseases including diabetic nephropathy, hHcys-induced
nephropathy, hypertension and obesity-related kidney diseases 1. It is imperative to understand
how this cascade of glomerular injury is instigated and amplified during redox signaling. In this
regards, the regulation of NOX activation is dependent on Rac-1 GTPase activity, in which
activated Rac stimulates the aggregation of the NOX complex as a functional enzyme to produce
O2.-. Vav2, a guanine nucleotide exchange factor may be key in Rac-1 activation.
The nucleotide-binding oligomerization domain Nod-like receptor containing pyrin domain
3 (NLRP3)-centered inflammasome has been well characterized as a redox sensor that turns on the
inflammatory response and instigates damage in the glomeruli, ultimately leading to glomerular
sclerosis. Activation of the NLRP3 inflammasome is considered ubiquitous in different organs and
cells and is a potent intracellular inflammatory machinery that proteolytically cleaves interleukin1β (IL-1 β) or IL-18 into their active forms 2–4. Some investigators believed that this inflammasome
activation may be the root of many chronic degenerative diseases. In the kidney, the formation and
activation of the NLRP3 inflammasome plays a critical role in a broad spectrum of glomerular and
tubulointerstital diseases as well as tubular injury and repair. Inhibition of this complex may serve
1

as an innovative therapeutic strategy to possibly prevent or treat glomerular diseases associated
with inflammation.
1.1 Hyperhomocysteinemia
HHcys has been identified as one of the leading pathogenic factors in the progression of
ESRD and it is also associated with an increased risk for cardiovascular complications. Amongst
the growing prevalence of chronic kidney disease (CKD), hHcys is a prevalent comorbidity
occurring in 85% of diagnosed patients 5. At present there are no diagnostic biomarkers for
accurately predicting these group of patients and with the prolonged clinical silence, it is a
challenge to completely reverse due to the functional abnormalities already present that develops
into fibrosis. The early mechanisms responsible for increased homocysteine (Hcys) levels during
ESRD or other associated kidney diseases still remain unclear. Prior studies have demonstrated
that a reduction in glomerular filtration rate (GFR) contributes to the increases in both serum
creatinine and Hcys

6–8

. Elevated concentrations of Hcys leads to endothelial damage and

dysfunction that progress into a buildup of extracellular matrix proteins, ultimately inducing renal
glomerular sclerosis and atherosclerosis

9–11

. It has become increasingly evident that hHcys may

result in glomerular degenerative diseases mainly through podocyte dysfunction and injury similar
to other metabolic disorders such as diabetes mellitus, where glomerular pathological
modifications will develop even in the absence of initiating factors.
More than 40 years ago, Dr. Kilmer S. McCully reported that elevated plasma Hcys level is
a key factor in the pathogenesis of cornary artery disease 9. Through extensive epidemiological
studies, high plasma Hcys has been implicated in numerous other conditions throughout the body
such as cardiovascular diseases

12–14

, stroke

15

, neurodengerative diseases

2

16

and ESRD

7,17,18

.

Patients with ESRD often develop hHcys with total blood Hcys (tHcys) levels of three times higher
than the normal range of < 10 μmol/L 19.
1.1.1 Homocysteine Metabolism
The kidney is a major participant in the homeostatic balance of amino acids and protein
metabolism; however, alterations in glomerular function have been closely linked with defective
synthesis, degradation or clearance, diet deficiencies and uremic cardiovascular complications
19,20

.
A basic illustration of the Hcys metabolic pathway is presented in Figure 1. Hcys is a

methionine-containing essential amino acid synthesized from food or the metabolism of
endogenous proteins. Following two separate enzymatic reactions methionine is converted into Sadenosyl methionine (SAM), a universal methyl donor for neurotransmitters, nucleic acids,
hormones and phospholipids. Demethylation of SAM yields S-adenosyl homocysteine (SAH)
which is hydrolyzed to form Hcys and adenosine as byproducts. At this phase in the metabolic
pathway, Hcys serves as a key regulatory molecule that can undergo remethylation or
transsulfuration to maintain a balance in Hcys concentrations

19,21

. If Hcys is remethylated back

to methionine by methionine synthase (MS), folate and cobalamin (vitamin B12) are required
cofactors. Alternatively, Hcys can undergo transsulfuration to cystathionine by cystathionine βsynthase (CBS), in an irreversible pyridoxal-5'-phosphate (vitamin B6) dependent reaction.
Cystathionine is then degraded into cysteine and converted into sulfates which are released in the
urine.
Normally 75% of total Hcys is covalently bound to a protein molecule, whereas the
remaining fraction is freely filtered through the glomeruli

21

. Disturbances in Hcys metabolism

have been linked to the progressive loss of kidney function, endothelial dysfunction and

3

atherogenesis 22. HHcys-associated nephropathy orginates from defective clearance of Hcys in the
plasma. There is an increasing body of evidence indicating that age, smoking, coffee consumption
and folate antagonist may also affect Hcys concentrations 21. In addition, alterations in enzymatic
activity and cofactors necessary for proper synthesis and catabolism have been associated with
overwhelmingly elevated plasma Hcys levels.

4

Figure 1. Homocysteine Metabolism.
Initially, dietary methionine is converted to S-adenosyl methionine (SAM); releasing of a methyl
group converts SAM to S-adenosylhomocysteine (SAH) by the enzyme SAH hydrolase.
Following hydrolase, SAH forms adenosine and Hcys. Once formed, Hcys then can be
remethylated into methionine by methylenetetrahydrofolate reductase (MTHFR) or degraded by
cystathione β-synthase (CBS) and γ-cystathionase.

5

1.1.2 Models of Hyperhomocysteinemia in Animals
Initial studies led by Dr. Kilmer S. McCully revealed children with mental retardation,
accelerated growth during childhood, dislocated ocular lenses and thrombosis were found to
excrete Hcys in the urine as well as advanced arteriosclerosis 9,23. Through careful review of these
clinical cases, Dr McCully discovered inherited abnormalities of the enzymes controlling
homocysteine levels in these patients. Several animal models of hHcys have been developed to
examine the effects of altered Hcys metabolism in the development of organ dysfunction and
progression of disease. Elevated Hcys concentrations can be induced by diet, gene knockouts or a
combination of both to investigate the causal role of Hcys in vivo. Dietary approaches include
addition of methionine to the diet; reducing the dietary content of vitamin B6 which prevents the
conversion of Hcys to cystathionine; limiting the remethylation of Hcys by implementing a diet
deficient in folate and/or vitamin B12 or adding Hcys directly to the drinking water 24. Modulations
of these factors in vivo have direct relevance to human disease progression, since low levels of
these vitamins are commonly seen in patients with hHcys. Additionally, hHcys can be induced by
deletion of CBS, MTHFR or MS, targeting of these enzymes in the Hcys metabolism pathway
mimic the inborn errors seen in patients with severe hHcys (Hcys > 100 μmol/L).
1.2 NAPDH Oxidase in the Kidney
An ever growing body of work has characterized the numerous intrarenal enzymatic systems
that contribute to the generation of reactive oxygen species (ROS). These sources include xanthine
oxidases, lipoxygenases, cyclo-oxygenases (COXs), P450 mono-oxygenases, mitochondrial
respiratory chain and NOX 25. However, the latter is considered the predominant source of O2.- in
the kidney

26

. Assembly of both membrane-associated (gp91phox and p22phox) and cytosolic

(p47phox, p40phox, and p67phox) subunits activates this complex, resulting in the shift of electrons to

6

molecular oxygen, leading to the generation of O2.- 25,27,28. Initial studies using a rodent model of
spontaneous hypertension reported upregulation of all NOX subunits localized in the renal cortex
29

. In addition, all components of the NOX complex have been documented to be prominently

expressed throughout the kidney including areas such as the renal vessels, tubules, interstitium and
glomeruli 30.
Under normal circumstances, ROS are short-lived species that are rapidly metabolized by
scavenging antioxidant enzymes. Low levels of ROS generated by NOX participate in normal
physiologic processes such as intracellular signaling as second messengers 31, mediating hormonal
effects

32,33

expression

, regulating ion channel activity, oxygen sensing 34, adipocyte differentiation 35, gene
31,36

, reproduction

37

, as well as cell growth, senescence, and apoptosis

38,39

. More

specifically, NOX-derived ROS are implicated in various physiological regulation in the kidney.
For example, the kidney maintains glucose homeostasis by participating in gluconeogenesis
(production of glucose to glutamine) in proximal tubular cells and reabsorbing filtered glucose into
the blood

28

. Type II diabetes is a chronic systematic disorder metabolically characterized by

elevated levels of glucose. Winiarska et al. demonstrated that pretreatment of apocynin, a known
NOX inhibitor reduced tubular cell gluconeogenesis in a diabetic rabbit model, indicating the
importance of NOX regulation during diabetic conditions in order to maintain glucose balance 40.
In addition, tubuloglomerular feedback is a crucial mechanism which regulates the hemodynamic
response upon alterations in tubular salt overload in the kidney
constriction of the afferent arteriole

41

28

. Production of O2.- leads to

and scavenging of nitric oxide in the macula densa

42

.

However, silencing of NOX and apocynin treatment inhibited high salt-induced O2.- generation 42.

7

1.2.1 Pathophysiological Role of NADPH Oxidase in the Kidney
During pathological conditions, renal NOX has been connected to oxidative stress and
disease progression. Metabolic disruptions in the kidney leads to increased renal NOX expression,
resulting in overproduction of ROS which disrupts the homeostatic balance and causes injurious
consequences by altering the structure and function of various lipids, proteins and DNA.
Generation of ROS exceeds the normal catabolism processes affecting the concentration in the
kidney.
We have documented that NOX-induced oxidative stress is crucial in the pathophysiological
role of renal injury associated with hHcys 43,44. Podocytes, known as the structural framework of
the glomerular filtration barrier are the most susceptible targets of injury in a number of renal
diseases. Following injury, podocytes become effaced, detached from the basement membrane and
undergo hypertrophy and apoptosis. We observed protection of podocyte structure and function in
gp91phox gene KO mice when they were exposed to hHcys 44. These mice exhibited significantly
attenuated proteinuria, foot process effacement and podocyte loss compared to their wild-type
counterparts. Additionally, inhibition of the gp91phox gene in cultured podocytes prevented Hcysinduced O2.- generation. We have also shown that NOX redox signaling mediates hHcys-induced
inflammasome activation inducing glomerular inflammatory injury and consequently leading to
glomerular sclerosis 43. Altogether, we have determined that podocyte ROS generation is an early
mechanism mediating hHcys-induced glomerulosclerosis. NOX-derived ROS generation is a
common observation related to other renal-associated pathologies including diabetes and
hypertension

30

. During focal and segmental glomerulosclerosis, the transient receptor potential

cation channel-6 (TRPC6) co-localizes with NOX to form a lipid raft signaling complex with the

8

podocyte specific protein, podocin, producing a localized burst of ROS that may modulate the
podocyte morphology and function 28.
1.2.2 Role of Rac-1 GTPase in NADPH Oxidase Regulation
During the NOX activating process, the major regulatory step necessary for activation of
NOX involves heterodimerization of gp91phox and p67phox mediated by the Rac protein. Rac-1
GTPase has been reported to rotate between two conformational states either a GDP-bound
“resting” state or GTP-bound “active” state. The transition between these two confirmations is
regulated by either GTPase activating proteins (GAPs), which stimulate the intrinsic GTPase
activation causing the switch to the resting condition or guanine nucleotide exchange factors
(GNEFs) that facilitate the exchange of GDP for GTP. Conversion to activated Rac-1 initiates the
translocation of the cytosolic subunits to the membrane, resulting in the formation of a functional
NOX complex

45,46

. It has been reported that the Vav subfamily represents distinct GNEFs with

high specificity to Rac-mediated NOX activation

47–49

. It is possible that the activation of Vav2

through elevated Hcys accelerates the switch from GDP to GTP, thereby enhancing NOX activity
and O2.- production.
1.3 NLRP3 Inflammasome in the Glomeruli
Both microbial and non-microbial inflammation has been reported to participate in
glomerular inflammatory responses, which may represent a critical pathogenic mechanism
responsible for glomerular injury and subsequent ESRD. In particular, the non-microbial
inflammation is widely recognized as a key pathological mechanism that mediates or promotes the
development of glomerular sclerotic pathology during ESRD associated with several common
systemic diseases such as hypertension, hHcys, diabetes mellitus, and erythematosus lupus

50,51

.

In this regard, activation of inflammatory responses in the residential renal cells may be critical in

9

initiating glomerular injury and renal dysfunction. There is evidence that glomerular IL-1β is
mainly generated from podocytes, but not other cell types. Increased IL-1β production from
podocytes are critically involved in the progression of many non-proliferative forms of
glomerulonephritis and other glomerular diseases induced by local inflammatory processes in
humans and rodents

52–54

. Using different approaches, our recent studies have shown that the 3

major NLRP3 components were indeed enriched in murine podocytes and that their assembling
into a multiprotein complex in podocytes occurs during stimulations by various danger factors
such as L-Hcys, uric acid crystals, and adipokine-visfatin 51,55. It has been proposed that NLRP3
inflammasome activation may importantly contribute to the onset or gradual progression of
glomerular injury under different pathological conditions 51,56,57.
1.3.1 NLRP3 inflammasome
Originally, the NLRP3 inflammasome was identified as a crucial player necessary for
activation of caspase-1, and the primary function is to activate cysteine proteases that subsequently
induce inflammatory responses in tissues or organs by generation of pro-inflammatory interleukins
(ILs)

23

. It is known that there are 23 Nod-like receptor (NLR) genes in the human genome

including the NLRP family that contains a pyrin domain and the NLRC family that contains a
caspase recruitment domain. Among all NLRs, only a few can be assembled into the
inflammasome to activate caspases 58, which are NLRP1, NLRC4, and NLRP3 inflammasomes.
NLRP1 was the first identified inflammasome, and it was found to provide immunity against
bacterial cell wall components, which directly activates caspase-5 without ASC (apoptosisassociated speck like protein with a caspase recruitment domain)
however, greatly accelerates NLRP1 inflammasome activity
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59,60

60

. The presence of ASC,

. Another NLR-associated

inflammasome is NLRC4, and its activation is only triggered by bacterial flagellin and endogenous
cell cytoplasmic components 61–63.
The NLRP3 inflammasome has been well characterized and its activation strongly links to
sterile inflammation in a variety of chronic degenerative diseases

64

. The NLRP3 gene was first

found to have mutations in patients with familial cold urticaria (FCU) and Muckle-Wells syndrome
(MWS)

65

. Consequently, the over exuberant inflammatory response seen in these patients was

attributed to an NLRP3-dependent mechanism that results in defective apoptosis and
transcriptional regulation. Further studies in these MWS patients demonstrated that they
spontaneously secrete active IL-1β, which is due to the interaction of NLRP3 with the ASC protein.
This interaction was later recognized as the formation of the NLRP3 inflammasome 66. Over the
last 5 years, many bacterial and viral pathogen-associated molecular patterns (PAMPs) and dangerassociated molecular patterns (DAMPs) released from damaged tissues or cells have been
identified as activators of the NLRP3 inflammasome. Tremendous efforts have been made
worldwide to address the possible role of this inflammasome in the initiation or development of
different diseases and to find inducers or activators of the NLRP3 inflammasome under different
pathological conditions, which may help identify therapeutic targets for treatment of related
diseases.
1.3.2 NLRP3 inflammasome activators
There are a very diverse range of danger factors that initiate activation of the NLRP3
inflammasome through different mechanisms. It has been reported that microbes such as the
influenza virus, adenoviruses, Staphylococcus aureus, E. coli, Neisseria gonorrhoeae, and
Candida albicans may stimulate NLRP3 inflammasome activation

67–72

. One of the mechanisms

activating the NLRP3 inflammasome during infections of these microorganisms may be associated
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with the formation of pannexin-1 channel that permits the entry of these microbial toxins into the
cytoplasm. In addition, monosodium urate (MSU) crystals, aluminum salts, silica or asbestos are
also reported to stimulate the NLRP3 inflammasome 2,73,74 and as non-microbial materials they are
phagocytosed into the cell leading to lysosomal damage, triggering NLRP3 inflammasome
activation to produce IL-1β and other cytokines. Additionally, extracellular ATP and potassium
were shown to induce NLRP3 assembly and activation, which may be mediated by the purinergic
P2X7 receptor and pannexin-1 75.
NLRP3 formation and activation have been originally attributed to auto-inflammatory
diseases and more than 20 such auto-inflammatory diseases can be treated by inhibition of NLRP3
activation and by antagonizing the action of IL-1β. Recently, many studies found that the
activation of the NLRP3 inflammasome also contributes to the development of various chronic
metabolic diseases such as diabetes mellitus, gout, silicosis, and obesity. In addition, in acute
myocardial infarction, atherosclerosis, glomerular sclerosis, Alzheimer’s disease and liver
cirrhosis the NLRP3 inflammasome is also shown to be activated

51,76–78

. In this regard,

accumulation of the amyloid-β protein in the brain is considered as an activator of the NLRP3
inflammasome to promote local inflammation or cell injury leading to the development of
Alzheimer’s disease 79. In addition, the high levels of IL-1β have been detected in the brains of
patients suffering from Alzheimer’s disease. During atherosclerosis, cholesterol crystals or even
oxidative products of cholesterol may serve as a danger factor to cause phagolysosomal damage,
activating the NLRP3 inflammasome and thereby promoting a pro-atherosclerotic phenotype in
arteries 80. In addition, trauma and excessive exercises may produce some chemokines that may
activate the NLRP3 inflammasome. This process may be associated with hyaluronan-mediated
cellular responses 81.
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In a murine model of diabetes, hyperglycemia stimulated NLRP3 inflammasome activation,
subsequently causing injury to pancreatic islet cells, glucose intolerance and insulin resistance 82.
Recent findings in our lab demonstrated that Hcys can stimulate NLRP3 inflammasome formation
and activation in different types of cells, if it is increased in blood or extracellular space. In
endothelial cells, this NLRP3 inflammasome activation will lead to endothelial dysfunction and
induce atherogenic effects. In podocytes, increased activation of the NLRP3 inflammasome results
in local glomerular inflammation and podocyte injury or transformation, ultimately leading to
glomerular sclerosis 51. We have shown that inhibition of the NLRP3 inflammasome via genetic
or pharmacological interventions prevented Hcys-induced podocyte injury and glomerular
sclerosis

51

. We also demonstrated that the adipokine, visfatin instigates vascular inflammation

and injury by activation of the NLRP3 inflammasome, which ultimately leads to atherosclerosis
81

. To our knowledge, increasing numbers of danger factors including PAMPs and DAMPs are

reported as activators of the NLRP3 inflammasome under different pathological conditions.
Therefore, the NLRP3 inflammasome is evolving as a new common pathogenic mechanism for
different diseases, in particular, those chronic degenerative diseases associated with inflammatory
pathology.
1.3.3 Mechanisms Mediating NLRP3 Inflammasome Activation
Detection of pathogenic microorganisms and sterile stressors, recruitment of ASC, caspase1 cleavage and production of inflammatory molecules are the main steps directing the pathological
path to NLRP3 inflammasome activation. Given that more than 120 substrates were predicted for
caspase-1, it is predictable that its maturation or activation will produce a variety of biological
responses in addition to production of cytokines. However, IL-1β and IL-18 are well-studied
products from the NLRP3 inflammasome. It is now known that the production of various cytokines
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via activation of caspase-1 triggers the inflammatory response and other cellular activities 83. In
phagocytes, the NLRP3 inflammasome activation follows a tightly regulated intracellular
signaling and regulatory process, which include two important steps. Initially, NF-κB initiates the
increased expression of genes encoding for inflammasome formation such as NLRP3, pro-caspase1, pro-IL-1β and pro-IL-18 4. This initial step is referred to as “priming”, which is influenced by a
cellular disturbance that activates pattern recognition receptors (PRRs). Signal II involves the
detection of PAMPS or DAMPs by NLRP3, which promotes the recruitment of the inflammasome
components to form the molecular complex 4. Aggregation of these molecules together leads to
the cleavage of pro-caspase-1 into two subunits, p10 (10 kDa) and p20 (20 kDa), and active
caspase-1 is the heterodimer

23

. Considerable evidence has indicated that the regulation of

inflammasome activity can be controlled by transcription of NLRP3 via signaling cytokine
receptors 84. Additionally, tight transcriptional regulation through microRNA, miR-223, influences
inflammasome activation by manipulating NLRP3 mRNA levels

85,86

. In some other cells

including endothelial cells, podocytes, neurons, epithelial cells and hepatic stellate cells, however,
a sustained and small scale inflammasome activation may not require the priming step. Several
signaling pathways have been reported to account for activation of the NLRP3 inflammasome.
Among them, potassium (K+) efflux, ROS generation, and cathepsin B leakage into the cytosol
due to phagolysosomal rupture are often studied 87. For example, an intracellular surge of K+ ions
into the cellular milieu is capable of triggering NLRP3 inflammasome activation. This model of
activation occurs when extracellular ATP interacts with gated cation channels like P2X7R or
bacterial toxins to produce pore formation

70,88

. Researchers have shown experimentally that

reduction of high K+ concentrations in cells diminishes the activation of the inflammasome,
although this molecular mechanism has not been characterized in all K+ efflux inflammasome
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inducers

89–91

. It has been reported that many inflammasome activators stimulate production of

ROS and these activators could be exogenous stimuli such as microbes or endogenously produced
or secreted molecules including DAMPs, Hcys and uric acids

92

. Uptake of particulate and

crystalline matter is reported to cause disruption of the lysosomal compartment causing cathepsin
B release that may lead to NLRP3 inflammasome activation 74,79,93.
In recent studies, we have demonstrated that during hHcys podocyte injury and glomerular
sclerosis are consequences of NLRP3 inflammasome activation

43,51,56

. We found that this

activation is associated with NOX-derived O2-. and related oxidants 43,94. Chemical scavengers and
pharmacological inhibitors of ROS were used to confirm that elevated plasma Hcys may serve as
a DAMP that activates the NLRP3 inflammasome in podocytes, which leads to podocyte
dysfunction, glomerular injury, inflammation and ultimate glomerular sclerosis

56

. It has been

suggested that DAMPs like Hcys, cholesterol, or visfatin may increase NOX activity via
membrane raft clustering to form lipid raft redox signaling platforms in podocytes or glomerular
endothelial cells, thereby producing O2.-. NLRP3 can sense and monitor intracellular redox
changes. If intracellular O2.- increases, it dissociates from thioredoxin-interacting protein (TXNIP)
and then binds to ASC, forming the NLRP3 inflammasome

56

where IL-1β, IL-18 and high

mobility group box 1 (HMGB1) are produced. These factors, in particular, IL-1β act to recruit
inflammatory cells to the glomeruli, in which O2.- and additional cytokines are generated, creating
a chronic sterile inflammatory cascade that contributes to glomerular injury and sclerosis.
Excessive amounts of active caspase-1 and IL-1β or other inflammasome products may reduce the
level of podocyte-specific proteins, nephrin and podocin, which will result in slit diaphragm
derangement and proteinuria. These inflammasome products may also directly induce podocyte
pyroptosis, consequently reducing podocyte numbers and causing foot process effacement 43,51,57.
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1.3.4 Effector Response of Inflammasome Activation
There is substantial evidence that activation of the NLRP3 inflammasome turns on
inflammatory responses, which may influence the progression to many chronic degenerative
disease including CKDs by eliciting damaging insults independent of inflammation

95

. This

NLRP3 inflammasome activation can cause both inflammatory and non-inflammatory effects 96.
In this regard, there is evidence that activated caspase-1 may act on more than 120 substrates and
that pyroptosis, enhanced glycolysis and lipid metabolism, altered cell survival and many other
direct effects during NLRP3 inflammasome activation may influence cell function and associated
metabolism. It is believed that the physiological or pathological role of activated NLRP3
inflammasome extends far beyond inflammation 97.
With respect to the classical pathway, various cellular proteins such as cytokines or
chemokines may be produced and secreted during NLRP3 inflammasome activation, which is
associated with an internal signal or amino-terminal that direct their translocation from the
endoplasmic reticulum (ER) lumen. These factors produced during inflammasome activation are
then actively transported to the Golgi complex, packaged into vesicles, fusing with the plasma
membrane and excreted out of the cells 98,99. Fibroblast growth factor 2 (FGF2), galectin 1 and 3
as well as mature IL-1β and the DAMPs including HMBG1 have been documented to be released
during NLRP3 inflammasome activation. These secreted factors induce inflammatory, cell
survival and repair reactions by activating cell surface receptors including FGF receptor-1, the IL
receptors, and the receptor for advanced glycation end-products (RAGE)

97

. Among these

cytokines or chemokines, IL-1β and IL-18 are often studied over the current years. Both have
extensive biological activities that result in the onset and development of inflammation as well as
in the disturbance of cell functions. Moreover, IL-1α, may also contribute to the inflammatory
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process. IL-1α, is released from necrotic cells and further processing of this interleukin is not
necessary because it descends from an active precursor 100. Interestingly, some recent studies have
indicated that almost all inflammasome activators are able to induce co-secretion of IL-1α with
other interleukin molecules

101

. However, IL-α release is not directly from the NLRP3

inflammasome activation, but may be dependent upon intermediate reactions after inflammasome
activation 4.
Pyroptosis, a specialized form of cell death serves as a non-inflammatory or non-canonical
effector mechanism during NLRP3 inflammasome activation. It is caspase-1 mediated and
proceeds independently of pro-inflammatory cytokine production. This form of cell death
enhances the immune responses by exposing foreign agents to the immune system’s surveillance
102

. Cytoplasmic swelling, osmotic lysis and release of intracellular molecules into the outside of

the cell are all characteristics of pyroptosis 97. Although attempts have been made to fill the gaps
in knowledge of pyroptosis, characterization of its molecular features still remains under debate.
A distinctive characteristic that may contribute to the pathogenesis of organ failure include the
abnormal overexpression of collagen leading to fibrosis 103. With the initial insult often unknown
in fibrosis, this form of wound healing can cause high mortality rates and proceed independent of
inflammation 103. In addition to pyroptosis, many other non-canonical effects induced by activation
of the NLRP3 inflammasomes or consequently enhanced caspase-1 activity include enhanced
glycolysis, abnormal cellular lipid metabolism, disturbance of cell survival programs, or altered
cell membrane permeability. These non-inflammatory effects may also contribute to the functional
and structural pathology of NLRP3 inflammasome activation in a variety of chronic degenerative
diseases.
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1.4 NLRP3 Inflammasomes in Glomerular Diseases
Growing evidence reveal that pathological progression of many kidney diseases originates
from inflammation as a result of renal injury. Routes to resolving renal damage involves activation
of transmembrane and intracellularly expressed PRRs as well as induction of transcriptional
inflammatory mediators that are crucial in the innate immune response and cellular homeostasis
104,105

, which may be reflected by the activation of the NLRP3 inflammasome. In the subsequent

section, we highlighted some evidence showing the implications of this inflammasome in the onset
or development of several different glomerular diseases.
1.4.1 Chronic glomerulonephritis (GN)
Chronic GN is referred to as inflammation of the glomeruli, which develops over several
years with no or very few symptoms, but causes irreversible kidney damage, ultimately leading to
ESRD. In GN, infiltrating mononuclear phagocytes generate canonical NLRP3 inflammasome
signaling, and the activation of NLRP3 inflammasomes also occurred in some non-immune
glomerular cells such as podocytes and glomerular capillary endothelial cells

52–54

. There is

evidence that in a rodent model of nephrotoxic serum nephritis (NTN) IL-1 and tumor necrosis
factor (TNF) are critical in promoting glomerular injury by interaction with the IL-1 receptor (IL1R) 106. Inflammasome signaling components were upregulated during NTN, in particular, in renal
dendritic cells, which led to increased production of mature IL-1β. In Nlrp3 and Asc gene knockout
mice having NTN, glomerular injury and related inflammatory responses such as leukocyte
infiltration or T-cell activation were significantly attenuated compared to their wild type
littermates. Interestingly, reduced secretion of active IL-1β was only observed in Asc knockout
mice, but not in Nlrp3-deficient mice, suggesting another potential molecular mechanism to be
involved, which is independent of the NLRP3 inflammasome. Additionally, NLRP3 may have
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non-canonical early inflammatory effects in NTN, which may be associated with glomerular
release of the inflammatory protein, HMGB1 in a NLRP3-mediated manner. This HMGB1 is
currently considered as one of the important mediators to promote the non-canonical functions of
NLRP3/ASC inflammasome activation 106.
Acute and chronic inflammatory responses have also been considered as an important
pathogenic mechanism of lupus nephritis (LN). Participation of the NLRP3 inflammasome may
promote the progression of LN 107. Recent studies have demonstrated that a selective inhibitor of
NLRP3 inflammasome activity, Bay11-7082, prevented assembling and activation of the
inflammasome and thereby decreased proteinuria, blood urea nitrogen, and glomerular damage
during LN. Accompanied with these beneficial effects, Bay11-7082 treatment also decreased renal
immune complex deposition and lowered the level of glomerular IL-1β, TNF-α and chemokine
(C-C Motif) ligand 2 (CCL2). The infiltration of macrophages was also found to be significantly
reduced. However, other studies have shown that active caspase-1 and renal secretion of proinflammatory cytokines such as IL-1β were not significant during acute heterologous NTN and
other glomerulonephritis

108

. It is clear that more studies are needed to further establish the

contribution of this inflammasome and other related molecular mechanisms in GN.
1.4.2 Hyperhomocysteinemic nephropathy
HHcys is characterized as a Hcys level that exceeds 15 µmol/L in the plasma of patients.
Elevated plasma Hcys levels have been linked to the progression of many chronic systemic
diseases including hypertension, peripheral vascular disease, Alzheimer’s disease, diabetes and
atherosclerosis 109. In regard to renal disease, hHcys is considered one of the important pathogenic
factors leading to the progression of ESRD. Additionally, the development of cardiovascular
complications related to ESRD has also been attributed to hHcys
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48

. Increasing evidence has

indicated that glomerular injury and ultimate sclerosis during chronic hHcys proceeds in a manner
independent of hypertension. Accumulation of Hcys in plasma or hHcys was shown to result in
the glomerular pathology including extracellular matrix accumulation and podocyte injury. Some
studies demonstrated that the inability of Hcys to be properly cleaned or degraded from blood
eventually leads to compromised renal function and glomerulosclerosis

110,111

. Although the

mechanism remains unclear on how Hcys causes cellular injury and sclerotic changes in many
organs and tissues, inflammatory cytokines were found increased in blood and many tissues during
hHcys. It has been indicated that the inflammation and related molecular machinery,
inflammasomes, may play a crucial role in these processes

112,113

. Under some pathological

conditions, Hcys-induced glomerular injury was indeed found to activate local inflammatory
responses by enhancing the production of monocyte chemoattractant protein 1 in glomerular
mesangial cells and tubular epithelial cells

114

. Inhibition of the inflammatory process could

significantly protect the kidney against hHcys-associated damage 114.
However, it remains poorly understood how the inflammation in glomeruli during hHcys is
activated and whether this is associated with NLRP3 inflammasome formation and activation. Our
recent studies revealed that treatment of glomerular epithelial cells (podocytes) with Hcys induced
the NLRP3 inflammasome, forming molecular complex and producing IL-1β and other cytokines.
This NLRP3 inflammasome activation critically contributes to the development of glomerular
sclerosis during hHcys. Moreover, there is evidence that knocking out of the Nlrp3 gene protected
podocytes and glomeruli against hHcys-induced injury as observed by decreased urinary protein
excretion, reduced glomerular damage and diminished expression of the podocyte-specific damage
marker, desmin in a mouse model of hHcys. The Nlrp3 gene has been well documented as an
essential component of NLRP3 inflammasomes, which serves as a sensor for monitoring redox
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changes. This sensing function of NLRP3 is confirmed to be mediated by its association and
dissociation with TXNIP 56.
1.4.3 Diabetic nephropathy
Diabetic nephropathy (DN) is the leading cause of ESRD and remains a great clinical concern
due to high mortality and morbidity rates. Poor management of diabetes often results in the loss of
renal function, which is due to gradual changes in the glomerular structure and associated functions
such as thickening of the basement membrane, mesangial expansion, proteinuria/albuminuria and
glomerular fibrosis. DN is different from other types of glomerular diseases that result in ESRD,
and it is generally categorized as a non-inflammatory glomerular disease. However, recent
genome-wide transcriptome analysis revealed that several inflammatory signaling pathways are
present or activated during DN. Although some reports have shown hyperglycemia-induced cell
death and immune cells accumulation in glomeruli, an inflammatory response, the precise
mechanisms by which inflammation is activated during DN remains to be elucidated 115.
More recent studies have now suggested that infiltration of inflammatory cells is crucial in
the pathogenesis of DN 116. IL-1β and IL-18 secreted from immune cells and glomerular resident
cells such as podocytes, endothelial cells or mesangial cells may possibly promote DN
Initial studies from Shahzad et al

117

51,54,117

.

revealed that diabetic mice have upregulated expression of

inflammasome molecules and pro-inflammatory cytokines in circulation when compared to their
non-diabetic counterparts. Morphological and progressive functional changes were also observed
in the kidney of these diabetic mice. In the db/db mouse model of diabetes, however,
transplantation of Nlrp3 and caspase-1 deficient mice bone marrow did not attenuate the kidney
damages compared to control db/db mice, suggesting that blocking of myeloid-lineage immune
cells is insufficient in preventing the progression to DN. In other studies, the production of
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mitochondrial ROS was shown to initiate NLRP3 inflammasome activation in diabetic conditions,
further establishing the causative link between NLRP3 inflammasome activation and DN. In
addition, inhibition of NLRP3 or caspase-1 in the kidney led to protective outcomes seen by
inactivation of the inflammasome. This provides a strong foundation in how the NLRP3
inflammasome serves as an important mediator for pro-inflammatory cytokine production by
caspase-1 activation and how inhibition of this complex formation may serve as a promising
approach to treat DN. With respect to the mechanism responsible for NLRP3 inflammasome
activation, it has been reported that high glucose (HG) treatment in mice induced NOX activity
triggering NLRP3 inflammasome activation in glomerular podocytes and leading to podocyte
injury during DN. However, inhibition of TXNIP by shRNA and its inhibitors abolished this DNinduced inflammasome activation 118. Since deletion of mouse Nlrp3 gene, antagonism of IL-1R
and inhibition of mitochondrial ROS production all were shown to protect or even reverse DN in
mice, targeting the NLRP3 inflammasome has been indicated to serve as a beneficial strategy for
treatment of DN 117.
1.4.4 Glomerular injury and sclerosis in obesity
CKD is now considered as one of the strongest risk factors for the morbidity and mortality
in obese patients, with the prevalence of obesity increasing worldwide 119,120. Previous studies have
identified visceral fat as a generator of bioactive substances that contribute to the pathophysiologic
and structural changes in glomeruli 121. Mechanistically, obesity-induced glomerular sclerosis and
ultimate ESRD is involved in chronic inflammation, abnormal glomerular vascular remodeling,
rise in renal plasma flow, hyperfiltration and renal lipotoxicity 122.
Most recently, we have indeed shown that the NLRP3 inflammasome is implicated in the
development of obesity and associated chronic glomerular injury. It serves as an important
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initiating mechanism to activate local glomerular inflammation leading to ultimate glomerular
sclerosis in obese mice

57

. Inhibition of the Asc gene significantly protected mice from high fat

diet (HFD)-induced obesity, podocyte damage and glomerular injury. Although the molecular
mechanism of HFD-induced inflammasome activation remains unknown, it is possible that
increased production of fatty acid metabolites, ceramide and palmitate is a key trigger. There is
evidence that the abundance of fatty acid metabolites in adipose tissue positively correlates with
the development of obesity and type II diabetes in mice. In this regard, Vandanmagsar et al
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showed that supplement of ceramide to adipose tissue explants led to NLRP3-dependent caspase1 activation and IL-1β production, suggesting that ceramide acts a danger signal to stimulate the
NLRP3 inflammasome. We have also shown that a HFD increased the glomerular ceramide
production due to the activation of acid sphingomyelinase, a ceramide producing enzyme. The
increased ceramide production induced the formation and activation of NLRP3 inflammasome in
glomeruli, which contributes to the obesity-induced glomerular injury. All these results have
indicated that the NLRP3 inflammasome may also be a therapeutic target for obesity and related
glomerular injury and sclerosis.
1.5 The NLRP3 Inflammasome as a Therapeutic Target in Chronic Glomerular Diseases
The prolonged period of clinical silence in chronic glomerular disease or CKD leads to
irreversible pathological damage leading to glomerular fibrosis. It has been well known that early
detection of these alterations and abnormalities in the impaired kidneys is necessary to facilitate
therapeutics that can improve clinical outcomes. Management of risk factors such as hypertension,
increase blood glucose level and albuminuria has been vital in slowing the progression to ESRD.
Although current treatments including angiotensin converting enzyme inhibitors (ACEi),
angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists and statins
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have

been used clinically for many years, the morbidity and mortality of CKD patients still remain high.
It is obvious that identification of new therapeutic targets and development of new strategies for
treatment of ESRD are imperative.
There is growing interest in administering anti-inflammatory therapies to halt renal and
cardiovascular functional loss, for example, targeting oxidative stress and inflammatory responses.
However, these therapies are met with a bit of skepticism and may only elicit partial improvements
in the pathogenic process of CKD characterized by glomerular sclerosis. The root of glomerular
dysfunction and other renal diseases previously associated with inflammation may potentially be
eliminated by inhibiting NLRP3 inflammasome activation. Convincing evidence has shown that
by blocking this complex there is a reduction in tissue and cellular inflammation. Because this
strategy targets both the non-inflammatory and non-canonical damaging effects on cell function
and metabolism, it may be more efficient during glomerular diseases. Indeed, treatments with IL1β antibodies have proven very effective in patients with cyropyrin-associated periodic syndromes
(CAPS) 125.
Activation of the NLRP3 inflammasome following MSU and other crystal-induced
pathologies translate into the disease manifestation of gout or pseudogout 2. There is also evidence
that antagonism of the IL-1 signaling pathway immediately improved the clinical outcome of
patients with these arthropathic diseases

126,127

. However, whether crystal-associated

nephropathies have the similar mechanisms has yet to be established. To our knowledge, approved
inhibitors of IL-1β are commercially available for treatment of various inflammasome-mediated
autoinflammatory diseases; however, they produced adverse effects at the injection site
Anakinra, a recombinant IL-1R antagonist competitively inhibits IL-1 signaling

128,129

130

.

, and

administration of Anakinra has been reported to improve the inflammatory response in
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hemodialysis patients

131

. In addition, Glyburide, commonly used to treat type II diabetes, was

found to block chloride and potassium channels in pancreatic β cells to regulate insulin release 132.
This compound is able to inhibit IL-1β release upon stimulation with LPS in human monocytes
133

, but it does not block capsase-1 activation unless Nlrp3, NF-κB or P2X7 genes are knocked out

in mice

134–137

. It is expected that more therapeutic strategies will be forthcoming. For example,

the use of NLRP3 inhibitors and the P2X7 receptor blockers may block NLRP3 inflammasome
activation. IL-1 and IL-18 receptor blockers, caspase-1 inhibitors can antagonize the effects of
NLRP3 inflammasome products, and H2S donor Na2S, lysosome stabilizer, cathepsin-B inhibitors,
and milk fat globule EGF-8 may serve as an endogenous inhibitor of inflammasome-induced IL1β production. These potential therapeutic strategies target different stages of NLRP3
inflammasome formation and activation, which may be selected for the use in prevention or
treatment of ESRD and associated glomerular diseases.
1.6 Aims of Study
The hypothesis to be tested in the present study states that: Vav2 associated redox signaling
associated with NOX contributes to Hcys-induced NLRP3 inflammasome formation and
activation, thereby causing glomerular inflammatory responses and associated pathologies.

In order to test this hypothesis the following specific aims were proposed:
1. To determine whether GNEF, Vav2 contributes to NLRP3 inflammasome activation and
associated podocyte injury and glomerular sclerosis in vivo in hyperhomocysteinemic
mice.
2. To determine whether Vav2 exerts its pathogenic role by activation of the Rac-1-NOX
complex, inducing NLRP3 inflammasome formation and activation in murine podocytes.
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3. To investigate pharmacological targeting of Vav2 as a potential therapeutic to prevent
CKD progression associated with hHcys-associated nephropathy.

The overall hypothesis and three specific aims of this project are schematically presented in
Figure 2.
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Figure 2. The Overall Hypothesis.
By inhibition and overexpression of the Vav2 gene, Aim 1 and 2 will demonstrate the role of
Vav2 in NOX-mediated redox signaling leading to NLRP3 inflammasome formation and
activation in podocytes. More specifically, these aims will reveal the involvement of Rac-1-NOX
signaling in the Hcys-induced sclerotic process. Aim 3 will further elucidate if Vav2 may serve
as a therapeutic target for termination of early events in hyperhomocysteinemic nephropathy and
ESRD.
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CHAPTER TWO
GENERAL METHODS

2.1 Hyperhomocysteinemic Mouse Model
Eight week old mice on a C57BL/6J background were purchased from Jackson Laboratories
(Bar Harbor, ME). To produce a rapid and advanced model of hHcys, mice were
uninephrectomized and afterward allowed 1-week to recover. Uninephrectomized mice were fed
either a normal diet (ND) or a folate-free (FF) diet to induce hHcys (Dyets Inc, Bethlehem, PA)
for 4 weeks. Before sacrifice, 24-hour urine samples were collected using mouse metabolic cages
and afterward blood samples were collected. The mice were then sacrificed and renal tissues were
harvested for biochemical and molecular analysis. All protocols were approved by the Institutional
Animal Care and Use Committee of Virginia Commonwealth University.
2.1.1 In vivo Treatments
For in vivo genetic studies, Vav2 short hairpin RNA (shRNA) or a dominant-active Vav2
variant (oncoVav2) plasmid with a luciferase expression vector was co-transfected into the kidneys
via a femoral artery injection using the ultrasound-microbubble system. Plasmid containing
scrambled small RNA (sRNA) was used as a control. After introduction of plasmid into the kidney,
these mice were maintained on either a ND or FF diet for 4 weeks.
For in vivo pharmacological studies, Nlrp3 knockout (Nlrp3-/-) mice were purchased from
the Mutant Mouse Research and Resource Center. Groups of mice received intraperitoneal (IP)
injections of the Vav2 activator, Uridine Triphosphate (UTP) or Rac-1 inhibitor, NSC-23766 (1
mg/kg/day) throughout the ND or FF diet feeding period, doses were chosen according to a recent
report 138.
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2.1.2 Ultrasound-microbubble Assisted Plasmid Transfection
After allowing one week for recovery from uninephrectomy surgery, a preparation of
plasmid encoding either Vav2 shRNA, oncoVav2 or the reporter gene luciferase was mixed with
cationically charged Optison microbubbles (GE Healthcare, Piscataway, NJ) then injected into the
femoral artery and locally transfected to the kidney by sonoporation with a continuous wave output
of 1 MHz at 10% power output at 30 sec intervals for a total of 6 minutes. To daily monitor the
efficiency of gene expression, mice were anesthetized with ketamine (100 mg/kg IP) and xylazine
(10 mg/kg IP), and an aqueous solution of luciferin (150 mg/kg IP) was injected 5 minutes before
imaging as described previously

48

. The anesthetized mice were imaged using the Xenogen

IVIS200 in vivo imaging system (Perkin Elmer, Waltham, MA). Photons emitted from luciferaseexpressing cells and transmitted through tissue layers were quantified over a defined period of
time ranging up to 5 minutes using the software program Living Image (Xenogen) as an overlay
on an Igor program (Wavemetrics). If transfection was not detected by in vivo imaging, the mice
were sacrificed and experiments terminated due to unsuccessful transgene expression.
2.2 Culture of Murine Podocytes
A conditionally immortalized mouse podocyte cell line gifted by Dr. Paul E. Klotman
(Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York,
NY, USA) was cultured undifferentiated with 10 U/mL recombinant mouse interferon-γ at 33°C
on collagen I-coated flasks in RPMI 1640 medium supplemented with 10% fetal bovine serum,
100 U/mL penicillin and 100 mg/mL streptomycin. Prior to experiments, podocytes were
thermoshifted at 37°C for 10-14 days to differentiate in the absence of interferon-γ and afterward
used for experiments.
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2.2.1 In vitro Treatments
Our previous studies have demonstrated a 40 µM treatment of L-Hcys for 24 hours to be the
optimal concentration and time to produce a significant activation of the NLRP3 inflammasome
43,56,107

. Pharmacological interventions of Vav2 UTP (100 µM) and NSC-23766 (50 µM) were

added to the cells 1 hour prior to Hcys treatment. Their doses for effective activation or inhibition
were confirmed in previous studies 139,140.
2.2.2 RNA interference
Podocytes were transfected with a scrambled sRNA, Vav2 shRNA or constitutively active
form of Vav2 (oncoVav2) plasmid directly to the nucleus via 4D- Nucleofector Technology
(Lonza, Basel, Switerland). The dominant active oncoVav2 plasmid containing an N-terminal
truncation was a generous gift from Dr. Keith Burridge from the University of North Carolina at
Chapel Hill 141. Small pores in the cell membrane develop temporarily through electrical impulses
and cell-specific solutions. Substrates are then delivered through the cytoplasm and into the
nuclear membrane. 2 x 106 podocyte cells were resuspended in SF Cell Line nucleofector solution
containing 2 μg plasmid shRNA or DNA, transferred into a certified cuvette and placed into the
nucleofector system. Podocytes were subjected to cell-type specific program CM-137, and then
resuspended in pre-warmed medium in cultured plates. An additional group of podocytes was used
to transfect Vav2 siRNA medium (Life Technologies, Carlsbad, CA) using the siLentFect Lipid
Reagent (Bio Rad, Berkeley, CA), which was incubated in serum-free for 25 minutes according to
the manufacturer’s instructions. After 4 hours incubation at 37ºC in both nucleo- and lipidtransfected cells, medium was replaced with fresh serum containing medium and podocytes were
allowed an overnight recovery prior to treatment with Hcys.

30

2.3 High Performance Liquid Chromatography (HPLC) Analysis of Plasma Hcys
Plasma Hcys levels were measured as previously described

142

by using 100 µL plasma or

standard solution mixed with 10 µL of internal standard, thionglycolic acid (2.0 mmol/L) then
treated with 10 µL of 10% tri-n-butylphosphine (TBP) solution in dimethylformamide at 4°C for
30 minutes. Then, 80 µL of ice-cold 10% trichloroacetic acid (TCA) in 1 mmol/L EDTA was
added and centrifuged to remove proteins in the sample. 100 µL of the supernatant was transferred
into the mixture of 20 µL of 1.55 M sodium hydroxide, 250 µL of 0.125 M borate buffer (pH 9.5),
and 100 µL of 1.0 mg/mL ABD-F solution. The resulting mixture was incubated at 60°C for 30
minutes to accomplish derivatization of thiols. HPLC was performed with a HP 1100 series
equipped with a binary pump, a vacuum degasser, a thermo stated column compartment, and an
auto sampler (Agilent Technologies, Waldbronn, Germany). Separation was carried out at an
ambient temperature on an analytical column, Supelco LC-18-DB (1504.6 mm ID, 5 m) with a
Supercoil LC-18 guard column (204.6 mm ID, 5 m). Fluorescence intensities were measured with
an excitation wavelength of 385 nm and emission wavelength of 515 nm by a Hewlett-Packard
Model 1046A fluorescence spectrophotometer. The peak area of the chromatographs was
quantified with a Hewlett-Packard 3392 integrator. The analytical column was eluted with 0.1 M
potassium dihydrogen phosphate buffer (pH 2.1) containing 6% acetonitrile (v/v) as the mobile
phase with a flow rate of 2.0 mL/min.
2.4 Confocal Microscopy and Immunofluorescence of Frozen Tissue and Cells
To observe colocalization of inflammasome and podocyte marker proteins, indirect
immunofluorescent staining was used in frozen tissue sections and podocytes. Podocytes seeded
in 8-well chambers were fixed in 4% paraformaldehyde (PFA), washed with phosphate-buffered
saline (PBS), and blocked with 1% bovine serum albumin (BSA) in PBS before being incubated
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in primary antibodies (1:100) overnight at 4°C. The primary goat anti-NLRP3 (Abcam,
Cambridge, MA) antibody was used in combination with the following: rabbit anti-ASC (Santa
Cruz, Santa Cruz, CA) or rabbit anti-caspase-1 (Santa Cruz). Frozen slides with mouse kidney
tissue were fixed in acetone, blocked with 3% donkey serum, then incubated with the same
aforementioned primary antibodies (1:50) overnight at 4°C. Additional groups of podocytes and
frozen kidney sections were only stained for antibodies against podocyte markers podocin (1:50;
Sigma, St. Louis, MO), desmin (1:50; BD Biosciences, San Jose, CA) or Vav2 (Santa Cruz, Santa
Cruz, CA). Double immunofluorescent staining was performed by Alexa-488 or Alexa-555labeled secondary antibodies (1:200 podocytes, 1:50 frozen kidney slides; Life Technologies,
Grand Island, NY) with an incubation of 1 hour at room temperature. Slides were then washed,
mounted and observed using a confocal laser scanning microscope (Fluoview FV1000, Olympus,
Japan) and tools in Image Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD) were used to
analyze colocalization, or the degree of overlap between the two wavelengths, which was
expressed as the Pearson Correlation Coefficient (PCC).
2.5 Immunohistochemistry
Kidneys were perfused in 4% PFA, removed and fixed in 10% neutral buffered formalin. 5μm tissue sections embedded in paraffin were cut and mounted onto microscope slides.
Deparaffination was induced through heat, tissue cleaning agent, ethanol and water. To unmask
antigen binding sites, slides were boiled in 0.01 M citrate buffer pH 6.0 for 20 minutes.
Endogenous peroxidase activity was blocked by incubating slides in 3% hydrogen peroxide
(H2O2) in 100% Methanol (MeOH) for 30 minutes. The sections were then incubated at room
temperature for 30 minutes in 10% goat serum to block nonspecific binding and incubated
overnight at 4°C in a humidified chamber with an antibody against IL-1β (Abcam, Cambridge,
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MA) diluted 1:50 in Tris Buffered Saline with 0.2% Tween (TBS-T) containing 4% goat serum.
Then, the slides were incubated for 30 minutes at room temperature in a humidified chamber with
a biotinylated goat anti-rabbit IgG-B antibody diluted 1:200 in TBS-T. These slides were
subsequently placed in streptavidin-horseradish peroxidase for 30 minutes at room temperature in
a humidified chamber, then incubated with 50 μL of diaminobenzadine (BioGenex, San Ramon,
CA) as a substrate, counterstained with hematoxylin (Sigma-Aldrich, Saint Louis, MO),
dehydrated, and fixed with Permount histological mounting medium (Fisher Scientific, Hampton,
NH).
2.6 Urinary Protein and Albumin Measurements
Total urinary protein excretion was determined spectrophotometrically using a Bradford
assay. Determination of urinary albumin was analyzed by a commercially available albumin
Enzyme-Linked Immunosorbent Assay (ELISA) kit (Bethyl Laboratories, Montgomery, TX). The
procedure for processing of albumin followed the instructions from the manufacturer. Briefly,
using an anti-rat albumin coated 96 well plate. The plate was washed 4 times in prepared wash
solution provided in kit, then incubated with an anti-albumin detection antibody urine samples
were diluted 1:200 in 1X dilution buffer and incubated for 1 hour at room temperature and exposed
to horseradish peroxidase (HRP) color substrate. Absorbance was analyzed by a microplate reader
using Gen5 software (BioTek, Winooski, VT).
2.7 Glomerular Morphological Examinations
Glomerular structure was examined using fixed paraffin-embedded kidneys, stained with a
Periodic-Acid Schiff (PAS) stain. Glomeruli were scored on a scale of 0-4 depending on the extent
of sclerotic changes. In general, 50 glomeruli were counted under the microscope, 0 represents no
lesion, 1 represents sclerosis <25% of the glomerulus while 2, 3 and 4 represent sclerosis of 25%
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to 50%, >50% to 75%, and >75% of the glomerulus respectively. A whole kidney average sclerosis
index was obtained by averaging scores from counted glomeruli. This observation was examined
by 2 investigators and averaged under blind conditions.
2.8 Cellular Protein Homogenates
Cultured podocytes were washed three times with ice-cold PBS and scraped in ice-cold
sucrose buffer (20 mM Tris-HCl, 250 mM sucrose, pH 7.2). Cellular extract was transferred into
a pre-chilled microcentrifuge tube and sonicated 3 times using a handheld sonicator for 10 pulses
on ice. Samples were incubated on ice for 30 minutes prior to centrifugation at 7,000 x g for 10
minutes at 4ºC to remove cellular debris. The supernatant was transferred to a new, pre-chilled
microcentrifuge tube and stored at -80ºC until used for biochemical analysis. Protein
concentrations were determined by the Braford Reagent Protein Assay method.
2.9 Western blot analysis
Expression levels of Vav2 were quantified in cultured mouse podocytes. Equal amounts of
protein samples were loaded onto a prepared 8% polyacrylamide gel and allowed to separate
electrophoretically at 120 Volts for 1 hour. Proteins from the gel were transferred onto
polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA) using a Mini Trans-Blot®
Electrophoretic Transfer Cell (Bio-Rad, Richmond, CA). Non-specific binding sites on the
membranes were blocked in 5% fat-free milk made in TBS-T for 1 hour at room temperature. The
PVDF membrane was then probed using a specific antibody against Vav2 and incubated at 4oC
overnight. The primary antibody used was mouse monoclonal anti-Vav2 (Santa-Cruz, Santa Cruz,
CA) diluted 1:1000. Membranes were washed three times for 10 minutes in TBS-T and incubated
with anti-mouse IgG-HRP (Santa Cruz, Santa Cruz, CA) for 1 hour, diluted 1:10,000 in TBS-T.
The membranes were then washed in TBS-T for 15 minutes three times, exposed to Super Signal
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West Pico Substrate Solution (Thermo Scientific, Rockford, IL) and protein bands were developed
by exposure to X-Ray film. The intensity of the protein bands were quantified by densitometry
using ImageJ Software.
2.10 RNA Isolation and Real Time RT-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from podocytes using TRIzol reagent (Thermo Fisher, Waltham,
MA) according to the protocol described by the manufacturer. The resultant RNA was resuspended
in RNase-free water and messenger RNA (mRNA) levels for Vav2 were analyzed by quantitative
reverse transcription using a Bio-Rad iCycler system (Bio Rad, Hercules, CA). The mRNA was
reverse transcribed to complementary DNA (cDNA) using an iScript cDNA synthesis kit (Bio
Rad). Real-time polymerase chain reaction (RT-PCR) was performed using a SYBR supermix kit
(Bio Rad) for 40 cycles at 95 ºC for 15 seconds and 53°C for 45 seconds. PCR efficiency was
examined by serially diluting the template cDNA and the melting curve data were collected to
check the PCR specificity. The mRNA levels of each sample for each gene were normalized to
that of β-Actin. The specific primers for Vav2 based on the core sequence of rat Vav2 cDNA
(Accession number XM_216030) were 5'- GTT CAA ACT CGG AAG TCA GG -3' (Forward)
and 5' CCA CGG GTA TGC AGT GTA AT -3' (Reverse).
2.11 Caspase-1 Activity, IL-1β Production and Vascular Endothelial Growth Factor (VEGF)
Measurements
Caspase-1 activity (Biovision, Mountain View, CA) was measured by a commercially
available colorimetric assay. IL-1β production (R&D Systems, Minneapolis, MN) and VEGF
(Bender Medsystems, San Diego, CA) were quantified through an ELISA using cellular
supernatant, according to manufacturer’s instructions.
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2.12 Rac-1 GTPase Activation Assay
A GTPase Linked Immunosorbent Assay (GLISA) was performed to determine Rac-1
activation in vitro (Cytoskeleton, Denver, CO). Podocytes were lysed in provided lysis buffer and
clarified to remove cellular debris by centrifugation at 10,000 x g for 1 minute at 4°C. Equalized
amounts of protein (1 mg/mL) was loaded onto a Rac-1 GTP affinity plate for 30 minutes.
Following incubation, the plate was washed in wash buffer then incubated with primary and
secondary antibodies against Rac-1. The activated Rac-1 was determined after exposure to HRP
detection reagents by measuring absorbance at 490 nm using a microplate spectrophotometer.
2.13 Electron Spin Resonance (ESR) Spectrophotometry of O2.- Production
Cellular protein samples were prepared by using modified Kreb's-Hepes buffer containing
deferoximine (100µM) and diethyldithio-carbamate (5 µM). NOX-dependent O2.- production was
examined by addition of 1 mM NADPH as a substrate in 30 µg protein in the presence or absence
of superoxide dismutase (SOD) (800 U/ml), and then supplied with 10 mM O2.- specific spin
trapping compound, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrro-lidine (CMH). The
mixture was loaded in glass capillaries and immediately analyzed for O2.- production kinetically
for 10 min in an ESR spectrometer. Results were obtained by subtracting the total CMH signal
without SOD, representing the SOD-specific signal. All values were expressed as the fold change
from control.
2.14 Statistical Analysis
All data are represented as mean + standard error (SE); n represents the number of
independent experiments unless otherwise stated. Differences in mean values within and between
multiple groups were analyzed using one-way analysis of variance (ANOVA) followed by
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Dunnett’s post hoc test. The statistically significant differences were also assessed by applying the
unpaired Student’s t test and the significance level was p<0.05.
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CHAPTER THREE
Contribution of guanine nucleotide exchange factor Vav2 to homocysteine-induced NLRP3
inflammasome activation in mouse podocytes during hyperhomocysteinemia
3.1 Rationale and Hypothesis
One of critical steps for NOX to induce glomerular injury may be due to activation of the
NLRP3 inflammasome, which senses the overall integrity and health of the cell. As illustrated in
Figure 3, the present study hypothesized that activation of Vav2 through elevated Hcys accelerates
the switch from GDP to GTP, thereby enhancing NOX-mediated activity and O2.- production,
which may instigate the cascade to glomerular sclerosis by activation of the NLRP3 inflammasome
in podocytes. To test this hypothesis, we first used 8 week old uninephrectomized mice on a
C57BL/6 background to examine the molecular participation of Vav2 in the actions of NLRP3
inflammasome formation and activation which results in glomerular inflammatory responses and
functional alterations in the glomerulus of hyperhomocysteinemic mice. Additionally, we explored
the molecular mechanisms by which Hcys results in an active Rac-1-NOX complex using cultured
murine podocytes.
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Figure 3. Representative schematic illustrating the goals of Aim 1 and 2.
Through genetic inhibition of Vav2 both in vivo and in vitro, Aims 1 and 2 will explore the
effects of Vav2 during hHcys.
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3.2 Results

3.2.1 Confirmation of hHcys-induced Model
Using HPLC analysis, we found that plasma Hcys concentrations was similar in all that
consumed the ND. However, we observed increased plasma Hcys levels in FF-fed Scram-, Vav2
shRNA- and oncoVav2-transfected mice, indicating a successful establishment of hHcys and that
Vav2 is not involved in Hcys metabolism (Figure 4).
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Figure 4. Effect of normal and FF diets on plasma Hcys concentrations.
Plasma Hcys levels measured by HPLC in 6 groups of mice (n=4). Scram: Scramble, Vav2sh:
Vav2 shRNA, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND.
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3.2.2 In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome formation
and activation
Using a hyperhomocysteinemic mouse model, we tested whether Vav2 facilitates hHcysinduced inflammasome formation and glomerular injury. By confocal microscopy, we found that
hHcys and oncoVav2 transfected mice fed a normal or FF diet exhibited increased colocalization
of NLRP3 with ASC and NLRP3 with caspase-1 (Figure 5). However, this colocalization was
inhibited in mice transfected with Vav2 shRNA (Figure 5). The summarized data is shown in
Figures 5C and 5D. Since activation of the NLRP3 inflammasome is associated with the
maturation of the pro-inflammatory cytokine, IL-1β, we measured the IL-1β levels in mouse
glomeruli using immunohistochemistry. We detected a significant increase in IL-1β levels in
hHcys mice and mice receiving the oncoVav2 plasmids on both normal and FF diets (Figure 6A).
However, blockade of Vav2 abolished further increases in hHcys-induced glomerular IL-1β
(Figure 6A). This data indicates that Vav2 is involved in both assembling and activation of the
NLRP3 inflammasome in glomeruli of mice with hHcys, which could be mimicked by
overexpression of Vav2.
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Figure 5. Inhibition of Vav2 abolished glomerular NLRP3 inflammasome formation
in mouse kidney.
A-B. Colocalization of NLRP3 (green) with ASC (red) or caspase-1 (red) in mouse
glomeruli fed a normal or FF diet. C-D. Summarized data showing the fold changes in PCC
for the colocalization of NLRP3 with ASC or with caspase-1 (n=6). Scram: Scramble,
Vav2sh: Vav2 shRNA, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on
ND; # p<0.05 vs. Scram on FF Diet.
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Figure 6. Vav2 overexpression induced NLRP3 inflammasome activation in podocytes of
the mouse kidney.
A. Representative images of immunohistochemical staining of IL-1β in glomerular podocytes
in mice on the normal or FF diet. B. Summarized data depicting relative intensity of IL-1β brown
staining (n=5). Scram: Scramble, Vav2sh: Vav2 shRNA, ND: Normal Diet and FF: Folate-Free
Diet. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on FF Diet.
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3.2.3 Glomerular protection by Vav2 inhibition
It is well recognized that protein in the urine is a hallmark of many glomerular diseases. After
a 24-hour urine collection, protein and albumin levels were evaluated in collected mouse urine to
serve as an indicator of glomerular injury. As illustrated in Figures 7A and 7B, the FF diet
produced both proteinuria and albuminuria in scramble sRNA-transfected mice, and the increased
urinary excretion of protein and albumin was also observed in oncoVav2 transfected mice on a
ND. However, this glomerular damage was attenuated in mice receiving intrarenal Vav2 shRNA
transfection (Figures 7A and 7B). Furthermore, this glomerular dysfunction was correlated to
modifications in the glomerular architecture as shown by morphological examinations. It was
found that scramble sRNA and oncoVav2 plasmid-transfected mice fed a FF diet developed
increased sclerotic damage to their glomeruli, as shown by mesangial expansion, fibrosis and
hypercellularity with an increased glomerular damage index (GDI) (Figures 7C and 7D).
Inhibition of Vav2 by shRNA protected mice from this glomerular sclerotic pathology.
Immunofluorescence analysis demonstrated that the expression of podocin decreased in oncoVav2
transfected mice on either the ND or the FF diet, but this decrease in podocin levels was not seen
in Vav2 shRNA transfected mice on the same diet (Figure 8A). In contrast, the levels of desmin,
a marker of podocyte injury, increased in oncoVav2 transfected mice, but not in Vav2 shRNA
transfected mice (Figure 8B). Furthermore, as shown in Figure 8C, Vav2 protein levels were
significantly lower in scramble sRNA and Vav2 shRNA transfected mice, as depicted by green
staining. Figure 8D showed the relative intensity of Vav2 staining in oncoVav2 transfected mice,
which exhibited a two-fold increase in comparison to that seen in scramble sRNA transfected mice.
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Figure 7. In vivo inhibition of Vav2 attenuated hHcys-induced glomerular damage.
Urinary protein (A) (n=4) and albumin (B) (n=5) measurements in 24 hr urine samples of hHcys
mice receiving shRNA- and onco-Vav2 transfection. C. Microscopic microphotograph of
glomerular structure in PAS stained kidney sections. D. Semiquantitative assessment of
glomerular damage index (GDI) from PAS images (n=4). Scram: Scramble, Vav2sh: Vav2
shRNA, ND: Normal Diet, FF: Folate-Free Diet, U: Urinary, and GDI: Glomerular Damage
Index. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on the FF Diet.
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Figure 8. Glomerular dysfunction associated with overexpressed Vav2 in mouse glomeruli.
A. Florescent staining of podocyte markers, podocin (A) and desmin (B) in mouse glomeruli (n
= 5). C. Confirmation of Vav2 (green) expression in glomerular podocytes. D. Quantification of
relative intensity of Vav2 in glomeruli (n=4). Scram: Scramble, Vav2sh: Vav2 shRNA, ND:
Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on the
FF Diet.
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3.2.4 Analysis of Vav2 expression in mouse podocytes
To verify efficiency of the Vav2 gene podocytes were co-transfected with the appropriate
plasmid encoding for either Vav2 shRNA or oncoVav2 with an amplified green fluorescent protein
(GFP) vector to visualize the transfected podocyte density. In Figure 9, representative images 48
hours-post transfection depict an intense stable gene expression in each group of transfected cells.
Using genetic manipulations, we observed Vav2 cellular protein levels (Figure 10B) and mRNA
expression (Figure 10C) were significantly increased 48 hours-post transfection of oncoVav2.
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Figure 9. Determination of podocyte density 48 hours post-transfection
A. Representative images of podocytes 48 hours post-transfection, displaying fluorescence, light
and merged overlay (n=4). Scram: Scramble and Vav2sh: Vav2 shRNA.
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Figure 10. Vav2 gene efficiency.
A. Western blot gel document and summarized data (B). C. RT-PCR detection of Vav2 mRNA
levels after shRNA and oncoVav2 transfection. (n=4) Scram: Scramble, Vav2sh: Vav2 shRNA,
sh: Vav2 shRNA, onco: oncoVav2 and kDA: kiloDalton. * p<0.05 vs. Scram.
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3.2.5 Role of Vav2 in Hcys-induced NLRP3 inflammasome formation in podocytes
The glomerulus is comprised of specialized cells that operate in a partnership to preserve the
integrity of the kidney. Evidence strongly links podocyte injury to the pathogenesis of many
glomerular diseases

143,144

. To better understand the impact of glomerular dysfunction during

hHcys, we chose to further investigate the molecular mechanisms initiating injury in podocytes by
employing cultured podocytes. Our initial studies determined if Vav2 is involved in Hcys-induced
inflammasome formation in these cells. By confocal microscopic analysis, we detected increased
colocalization of NLRP3 with ASC or caspase-1 in Hcys-treated podocytes when compared with
untreated cells (Figure 11). However, this Hcys-induced increase in colocalization was inhibited
in podocytes transfected with Vav2 shRNA (Figure 11). Additionally, oncoVav2 overexpression
increased colocalization of inflammasome molecules in both control and Hcys-treated groups of
podocytes. The quantitative colocalization of NLRP3 with ASC or caspase-1 is summarized in
Figures 11C and 11D.
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Figure 11. Hcys treatment and oncoVav2 transfection increased NLRP3 inflammasome
formation in podocytes.
A-B. Confocal images signifying the colocalization of NLRP3 (green) with ASC (red) and
NLRP3 (green) with caspase-1 (red) in cultured podocytes transfected with Vav2sh or
oncoVav2. C-D. Summarized data showing the fold change in PCC colocalization (n=6). Scram:
Scramble, Vav2sh: Vav2 shRNA and Ctrl: Control. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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3.2.6 Activation of the NLRP3 inflammasome in vitro
We confirmed the role of Vav2 in Hcys-induced inflammasome activation by measuring the
levels of active or cleaved caspase-1 and the level of secreted IL-1β. As shown in Figure 12, Hcys
treatment increased caspase-1 activity and IL-1β production in comparison to control podocytes.
Hcys-induced increase in caspase-1 activity and elevation in IL-1β levels were significantly
attenuated in podocytes transfected with Vav2 shRNA (Figure 12). Transfection with oncoVav2
mimicked the effects of Hcys which increased caspase-1 activity and elevated IL-1β levels in
cultured podocytes (Figure 12).
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Figure 12. In vitro induction of NLRP3 inflammasome activation in podocytes,
independent of Hcys treatment.
A. Caspase-1 activity, shown as fold vs. Ctrl, measured in transfected podocytes treated with
Hcys (n=5). B. IL-1β production measured in the supernatant of transfected podocytes treated
with Hcys (n=6). Scram: Scramble; Vav2sh: Vav2 shRNA. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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3.2.7 Inhibition of Vav2 improves podocytes damage
We further assessed the participation of Vav2 in podocyte dysfunction induced by Hcys. It
was found that upon stimulation with Hcys, there was decreased staining of the podocyte marker
podocin in Hcys-treated and oncoVav2-transfected podocytes, whereas desmin levels increased in
these groups, suggesting damage to podocytes (Figure 13A). However, Vav2 shRNA reversed
Hcys-induced podocyte damage (Figure 13A). Additionally, we observed that Hcys treatment and
oncoVav2 transfection resulted in significant impairment of podocytes to secrete vascular
endothelial growth factor (VEGF), a major product of healthy and mature podocytes (Figure 13B).
Inhibition of Vav2 protected podocytes from such injury or dysfunction, which was seen by
restored levels of VEGF secretion (Figure 13B).
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Figure 13. NOX activation by Vav2 overexpression promoted podocyte dysfunction.
A. Podocin (red) and desmin (blue) staining following Hcys treatment (n = 5). B. Measurement
of secreted VEGF in cellular supernatant (n=7). Scram: Scramble; Vav2sh: Vav2 shRNA;
Vav2si: Vav2 siRNA, * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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3.2.8 Effect of Rac-1 activation on Hcys-induced NOX activity
It is well-defined that activated Rac serves as an anchor protein to regulate NOX activity in
many cell types 145–147. We have shown that Hcys treatment and oncoVav2 transfection resulted in
increased Rac-1 activation in cultured podocytes (Figure 14A). A significant decrease in Rac-1
activity was observed in podocytes with silenced Vav2 gene, suggesting that more Rac-1 remains
in the GDP-bound or inactive state (Figure 14A). Coupled with increased GTP-bound Rac-1, we
also found that oncoVav2 transfection produced a great increase in O2 .-, which was inhibited in
the Vav2 shRNA transfected podocytes (Figure 14B).
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Figure 14. Vav2 blockade prevented in vitro inhibition of NOX-derived O2.- production.
A. Rac-1 activity (n=6) and O2.- production (n=5) (B) in Vav2- and oncoVav2-transfected
podocytes in the presence or absence of Hcys. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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3.3 Summary
In summary, the results from these experiments signify that Vav2 is critically involved in
Hcys-induced NLRP3 inflammasome formation and activation, which may critically contribute to
podocyte dysfunction and glomerular injury. These results demonstrate that Rac-1-NOX activation
and subsequent production of O2 .- are main triggering mechanisms of the NLRP3 inflammasome
in podocytes, which is consistent with previous reports 56,94. Vav2 may be a therapeutic target for
termination of early events in hyperhomocysteinemic nephropathy and ESRD.
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CHAPTER FOUR
Pharmacological targeting of Vav2 to inhibit the NLRP3 inflammasome and glomerular
injury during hHcys
4.1 Rationale and Hypothesis
We have established that Vav2 signaling initiates a pathogenic mechanism facilitating
hHcys-induced glomerular injury by activation of the NLRP3 inflammasome. This multi-protein
complex has been shown to elicit direct damaging insults both inflammatory and noninflammatory, suggesting that its activation may turn on glomerular inflammation and other
cellular damages, contributing to the onset of glomerular injury and ESRD. We have shown from
the chapter above that Vav2 is functionally required to initiate the progression of these downstream
signaling events, indicating that targeting of Vav2 signaling could potentially serve as an
innovative therapeutic to halt glomerular damage associated with hHcys (Figure 15). To test this
hypothesis, we administered pharmacological interventions of Vav2 signaling to glomerular
epithelial cells and Nlrp3-/- mice.
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Figure 15. Representative schematic illustrating the goal of Aim 3.
Aim 3 will investigate the targeting of Vav2, pharmacologically to prevent or treat hHcysinduced inflammasome activation and glomerular injury.
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4.1 Results
4.2.1 Rac-1 inhibition by NSC23766 ameliorated Hcys-induced inflammasome activation and
podocyte injury in vitro
To determine whether targeting of Vav2 can prevent excessive NLRP3 inflammasome
signaling during Hcys-induced injury, podocytes were treated with either uridine triphosphate
(UTP), a Vav2 activator or NSC23766, a selective inhibitor of Rac-1 in the presence or absence of
Hcys. As depicted in Figure 16, pretreatment of podocytes with UTP and Hcys resulted in a
significant elevation of GTP-bound Rac in comparison to untreated cells. However, NSC23766
treatment blocked Hcys-induced Rac GTPase activity. By confocal microscopy, we demonstrated
that following Hcys treatment, podocytes increased colocalization of NLRP3 with ASC or caspase1 in comparison to control cells (Figures 17A and Figure 17B). Stimulation of podocytes with
UTP, mimicked this Hcys-induced inflammasome formation and had no further enhancing effects
on Hcys response (Figures 17A and Figure 17B). Pretreatment with NSC23766, blocked Hcysinduced increases in inflammasome formation as shown by reduced NLRP3 colocalization with
ASC or caspase-1 (Figure 17A and Figure 17B). Using caspase-1 activity and IL-1β production
as indicators of NLRP3 inflammasome activation, we found increased activation of caspase-1 in
Hcys-treated podocytes, and prior treatment of podocytes with NSC23766 led to attenuated
caspase-1 levels (Figure 18A). Similar to Hcys, UTP treatment increased the level of cleaved
caspase-1 (Figure 18A). Elevated production of IL-1β displayed in Hcys- and UTP treated
podocytes, signifying inflammasome activation (Figure 18B). Inhibition of Rac-1, by preincubation of NSC23766 reduced IL-1β production in Hcys-induced podocytes (Figure 18B).
During glomerular podocyte maturation, VEGF is secreted from the cell and is an essential
molecule necessary for podocyte survival and function. We observed in both Hcys- and UTP-
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injured podocytes VEGF secretion was significantly reduced in comparison to control cells
(Figure 19). Additionally, prior treatment with NSC23766 resulted in increased secretion of
VEGF, indicating preserved podocyte function (Figure 19).
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Figure 16. NSC23766 attenuated Hcys-induced Rac-1 activation.
A. Rac-1 activity in UTP-and NSC23766-treated podocytes (n=3).Vehl: Vehicle and NSC:
NSC23766, * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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Figure 17. Rac-1 Inhibition prevented Hcys-induced NLRP3 inflammasome formation.
Confocal microscopy analysis of NLRP3 (green) with ASC (red) (A) and NLRP3 (green) with
caspase-1 (red) (B) in treated podocytes. C-D. Summarized data showing the quantification of
colocalization of inflammasome components (n=3). Vehl: Vehicle and NSC: NSC23766, *
p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.
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Figure 18. Inhibition of Vav2 attenuated Hcys-induced NLRP3 inflammasome activation.
Effect of inhibition of Vav2 on caspase-1 activity (A) and IL-1β production (B) induced by Hcys
in podocytes treated with UTP or NSC23766 (n=6). Vehl: Vehicle and NSC: NSC23766, *
p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.

66

Figure 19. Blockade of Vav2 signaling maintained podocyte function.
A. Measurement of VEGF secretion as a podocyte function parameter was detected in the
supernatant of treated podocytes (n=6). Vehl: Vehicle and NSC: NSC23766, * p<0.05 vs. Ctrl;
# p<0.05 vs. Hcys.
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4.2.2 Mouse Nlrp3 gene deletion and Vav2 inhibition prevented hHcys-induced NLRP3
inflammasome formation and activation in glomeruli
To further determine whether targeting of Vav2 signaling attenuates hHcys-induced NLRP3
inflammasome formation and activation in vivo, Nlrp3-/- (KO) and Nlrp3+/+ (WT) mice were
administered UTP or NSC23766, intraperitoneally and fed either a ND or FF diet for 4 weeks.
Approximation of plasma Hcys concentration was evaluated by HPLC. In both KO and WT mice
consuming the FF diet significantly increased total Hcys levels in comparison to their ND-fed
littermates (Figure 20). Neither gene deletion nor treatment with UTP or NSC23766 altered Hcys
levels. As shown in Figures 21, hHcys Nlrp3+/+ mice as well as those mice administered UTP
displayed increased inflammasome formation seen by colocalization of inflammasome
components, NLRP3 with ASC and NLRP3 with caspase-1 as well as increased IL-1β production
in the glomeruli, indicating inflammasome activation (Figure 22). However, this formation and
activation was inhibited in hHcys Nlrp3-/- mice and mice receiving NSC injections (Figure 21 and
Figure 22). The summarized data of quantitative colocalization of NLRP3 with ASC or with
caspase-1 in glomeruli of mice were shown in Figures 21C and 21D.
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Figure 20. Effects of gene knockout or in vivo UTP and NSC23766 administration on FF
diet-induced Hcys concentration.
A. Plasma Hcys levels measured by HPLC in Nlrp3-/- and Nlrp3+/+ mice (n=1-7). Vehl: Vehicle,
NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Vehl on ND.
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Figure 21. HHcys and UTP administration induces NLRP3 inflammasome formation.
Colocalization of NLRP3 (green) with ASC and NLRP3 with caspase-1 (red) in mouse
glomeruli following UTP or NSC23766 administration in FF- or ND-fed mice (n=3). Vehl:
Vehicle, NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on
ND. * p<0.05 vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet.

70

Figure 22. In vivo administration of NSC23766 attenuated NLRP3 inflammasome
activation.
A. Immunohistochemical staining of IL-1β in glomerular podocytes (n=2). Vehl: Vehicle, NSC:
NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND. * p<0.05
vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet.
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4.2.3 Administration of NSC23766 protected glomerular podocytes from hHcys-induced
dysfunction and injury
To assess whether inflammasome-mediated glomerular damage is a consequence associated
with podocyte dysfunction we determined the expression levels of podocyte specific markers,
podocin and desmin by immunofluorescence analysis. Our results displayed that in both hHcys
Nlrp3+/+ mice and UTP-treated mice there was dramatic decreases in podocin staining (Figure
23A). Rac-1 inhibition by NSC23766 administration resulted in ameliorated hHcys-induced
glomerular damage shown by restoration of podocin expression levels (Figure 23A). Moreover,
Nlrp3+/+ UTP treated mice exhibited a high abundance of desmin expression in glomeruli of both
ND and FF-fed groups, whereas NSC23766 administration protected against hHcys-induced
increases in glomerular desmin in Nlrp3+/+ mice, with similar expression levels as the Nlrp3+/+ mice
on a ND (Figure 23B).
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Figure 23. NSC23766 protected glomerular podocytes from dysfunction.
Immunofluorescent staining of podocin (A) and desmin (B), podocyte-specific markers (n=3).
Vehl: Vehicle, NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram
on ND. * p<0.05 vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet.
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4.3 Summary
Taken together, our results demonstrate that blockade of Vav2 exchange activity diminished
NLRP3 inflammasome formation and activation in vitro and in vivo. Additionally, inhibition of
the NLRP3 inflammasome protected podocytes from the early adverse effects of increased Hcys,
demonstrating that tight regulation of the NLRP3 inflammasome by intervention of Vav2
activation could prevent unwarranted damage and excessive inflammation seen in hHcysassociated glomerular injury.
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CHAPTER FIVE
DISCUSSION

5.1 Activation of NADPH oxidase by Vav2 overexpression is sufficient to activate the NLRP3
inflammasome in glomerular podocytes, independent of hHcys
The primary goal of this study was to reveal the involvement of the GNEF, Vav2 in activation
of the NLRP3 inflammasome during hHcys. Our results showed that Vav2 inhibition by RNA
interference attenuated hHcys-induced NLRP3 inflammasome formation and activation in
podocytes. Conversely, overexpression of Vav2 resulted in enhanced inflammasome formation
and activation in these cells independent of Hcys treatment. Results from the present study also
demonstrated that Vav2 inhibition protected podocytes against Hcys-induced glomerular injury.
This Vav2-mediated action was associated with NOX activation and increased ROS production in
glomeruli.
Distinctive GNEFs facilitate the conversion of GDP for GTP, inciting Rho protein activation
148

. Among more than 100 GNEFs, the Vav subfamily is highly selective in coordinating

intracellular signal transduction pathways associated with NOX activation

141,149

. Our earlier

studies have demonstrated that of 3 Vav isoforms, both Vav2 and Vav3 are localized in the
glomeruli, whereas it is already established in other reports that Vav1 is solely present in
hematopoietic cells

48

. We have shown that by sensing intracellular ROS during hHcys,

thioredoxin-interacting protein (TXNIP) associates with NLRP3 to trigger the cascade of
downstream events leading to inflammasome activation

56

. Recently, evidence links Vav2 as a

binding partner of TXNIP 150. Therefore, we sought to identify whether the detrimental actions of
Vav2 are involved in NLRP3 inflammasome assembling, activation and subsequent podocyte
75

dysfunction. It has been reported that internal or external danger signals are capable of initiating
the recruitment of ASC and caspase-1 forming the NLRP3 inflammasome complex

2,50

. This

inflammasome complex triggers the production of IL-1β and IL-18, inducing a heightened
inflammatory response. Processing of not only the interleukins, but also caspase-1 is considered
crucial in the inflammatory process that leads to tissue injury, organ or systemic diseases

96

. In

particular, NLRP3 inflammasome activation has been implicated in the pathogenesis of various
renal diseases including acute kidney injury, chronic kidney disease, diabetic nephropathy, crystal
related nephropathy and hyperhomocysteinemic nephropathy

3,151,152

. Renal cells such as

podocytes have been documented as the main enriched sites for maturation of glomerular IL-1β
production 43,107.
To our knowledge, we are the first to report that silencing the Vav2 gene and reduction of its
activity using genetic manipulations inhibited the NLRP3 inflammasome by preventing the
activation of the small GTPase, Rac-1. Consistent in both our in vivo and in vitro models, our
results show that Vav2 shRNA interventions decreased the interactions of inflammasome
components NLRP3, ASC and caspase-1 (Figures 5 and 11). Consequently, the absence of
inflammasome machinery resulted in decreased IL-1β production in mouse glomeruli (Figure 6)
which was associated with diminished caspase-1 activity in podocytes (Figure 12). The most
remarkable finding in the present study was that Vav2 overexpression triggered NLRP3
inflammasome formation irrespective of Hcys exposure (Figure 5 and 11), suggesting that Vav2 is
crucial in bridging the redox signals derived from NOX activity and NLRP3 inflammasome
activation, which may be a critical mechanism responsible for glomerular inflammatory response
during hHcys.
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There is evidence that abundance of protein leaked in the urine and excessive reabsorption
of protein in renal proximal tubular cells are linked to the pathophysiological states of renal disease
development

153,154

. In this regard, Connell et al. demonstrated that in response to albumin

overloads, proximal tubule cells encounter direct toxic effects associated with Rac GTPase and
NOX activation as well as receptor-mediated endocytosis 155. Our results add to this by showing
that mice with overexpressed Vav2 had typical features of glomerular damage as evidenced by
proteinuria, albuminuria and increased GDI (Figure 7). Downregulation of the Vav2 gene
effectively ameliorated these detrimental effects in mouse glomeruli. With respect to the
mechanism of glomerular injury during different pathological conditions such as hHcys, podocyte
injury is considered to play an important role. It has been reported that disruption of the slit
diaphragm, actin rearrangement and foot process effacement are unique indicators of podocyte
injury

143,156

. Our data revealed that Hcys treatment and Vav2 overexpression decreased a

podocyte-specific molecule, podocin (Figure 8 and 13), which may result in derangement of the
slit diaphragm structure and related cell signaling pathways

156

. Furthermore, resultant injury to

podocytes may lead to the upregulation of the intermediate filament, desmin, which was indeed
confirmed in our studies as shown by increased desmin levels in podocytes during hHcys or
exposure to high levels of extracellular Hcys. Interestingly, this desmin increase in podocytes
during hHcys could be blocked by shRNA of Vav2, but mimicked by oncoVav2 transfection. The
results suggest that Vav2 critically contributes to hHcys-induced podocyte injury and glomerular
sclerosis.
To explore the mechanisms by which Vav2 activates the NLRP3 inflammasome and thereby
lead to podocyte injury and glomerular sclerosis, we examined the effects of Vav2 interventions
on Rac activity and consequent NOX activation. It is well known that instigation of NOX as a
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functional signaling complex is dependent on the translocation of its cytosolic subunits (p47phox
and p67phox) to the membrane in which this platform initiates the generation of superoxide (O2 .-)
25,157

. The Rac protein is crucial in these migratory events, serving as a binary switch that cycles

between active GTP-bound and inactive GDP-bound states. However, the molecular cues directly
responsible for Rac protein activation and subsequent NOX activity following prolonged exposure
to Hcys remained unclear. From our findings, we confirm that expression of constitutively active
Vav2, can itself drive the activation of the Rac-1 protein (Figure 14A) and the aggregation of a
functional NOX complex, which produces O2

.-

even without Hcys stimulus (Figure 14B).

Moreover, blockade of Vav2 attenuated enhancement of Rac activity and O2 .- generation, even in
the presence of Hcys, a known activator of ROS. Results from these experiments illustrate that
Vav2 can promote injurious consequences in podocytes and that inhibition of Vav2 function may
terminate the development and progression of Hcys-induced podocyte injury and consequent
glomerular sclerosis.
5.2 Inhibition of Vav2 signaling by NSC23766 ameliorated hhHcys-induced glomerular
dysfunction
In the present study, we clearly demonstrated that inhibition of Vav2 exchange activity by
administration of NSC23766 prevented upregulation of Rac-1 GTPase production in Hcys-treated
podocytes, resulting in attenuated NLRP3 inflammasome formation, inhibition of caspase-1
activation and a subsequent reduction in IL-1β processing and release. Additionally, we showed
that administration of NSC23766 in vivo attenuated excessive hHcys-induced inflammasome
activation and glomerular dysfunction, thus highlighting the significance of pharmacologically
targeting Vav2 activity.
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ESRD is regarded as one of the world’s most prevalent chronic disorders

7,154

. Although

many therapeutic approaches focus on slowing the progression of renal failure, alleviating the
severity of symptoms, management of risk factors and prolonging life remain a large challenge
clinically given that many patients in the early stages of CKD are asymptomatic. Therefore, early
diagnosis and effective interventions are crucial in management and amelioration of kidney injury.
We have found that the underlying mechanism associated with Hcys-induced podocyte
dysfunction and injury is dependent on the activation of Vav2. Expression of Vav2 in podocytes
promotes the activation of Rac-1 which leads to the aggregation of the multi-protein NOX
complex, promoting O2.- production, inflammasome activation and initiation of glomerular injury.
Progression of these downstream signaling events are primary contributing factors associated with
hHcys-induced nephropathy. It is clear that novel therapies to target Vav2 and the inflammasome
may be an important therapeutic strategy to lessen the extent of glomerular injury.
In our previous studies, we revealed that the Nlrp3 gene is a critical component necessary
for assembling and corresponding injury during hHcys 158. Furthermore, we reported that chronic
elevations of Hcys contribute to the development of glomerular disease independent of
hypertension

159

. In previous studies, Nlrp3 deficient mice have been reported to have cardio-

protective effects during myocardial ischemia 160 as well as protection against pancreatic damage
associated with diet-induced obesity

161

. Utilization of these mice in our study demonstrated

remarkable protection against hHcys-induced inflammasome activation and glomerular injury.
Additionally, using a Rac-1 selective inhibitor in Nlrp3+/+ mice proved to exhibit reno-protective
effects against hHcys-induced alterations in the glomeruli. We found that these mice had
attenuated inflammasome formation (Figure 21), enhanced podocin expression (Figure 23) and a
downregulation of the injury marker, desmin (Figure 23). In vitro, following pretreatment of
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glomerular podocytes with Rac-1 inhibitor, NSC23766 abolished Hcys-induced inflammasome
formation (Figure 17) and activation (Figure 18). Through biochemical analysis we also observed
protective effects associated with increased VEGF secretion in this group of podocytes (Figure
19). Taken together, these results confirm that the Nlrp3 gene mediates hHcys-induced
inflammasome formation and activation, but most significantly these findings demonstrate that
pharmacological modification of Vav2 exchange activity abolished these pathological events
associated with increased Hcys.

5.3 Significance and perspectives
There is indeed increasing evidence for an association between glomerular diseases and
NLRP3 inflammasome activation, which leads to caspase-1-mediated IL-1β/IL-18 production.
More knowledge is needed in this area to further assess the underlying relationship between the
NLRP3 inflammasome activation and decline of glomerular function in various chronic kidney
diseases, in particular, to define the temperospatial contribution of the activated inflammasomes
to the onset or development of glomerular disease and ultimate ESRD. Moreover, recognition and
clarification of the non-canonical effects of NLRP3 inflammasome activation in glomeruli as well
as the alternative pathways to activate this inflammasome may be particularly interesting and
important, because this non-canonical action and alternative inflammasome activating pathways
may result in a combination of injurious actions independent of typical inflammation. Possible
direct damage to glomerular cells, interference with synthesis of cell-specific proteins, enhanced
cell membrane permeability and cell pyroptosis may importantly contribute to glomerular injury
during NLRP3 inflammasome activation in response to pathological stimuli. These direct effects
of NLRP3 inflammasome activation may suggest a new therapeutic strategy for treatment and
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prevention of glomerular sclerosis and ESRD, namely, targeting the NLRP3 inflammasomemediated uncanonical mechanism responsible for glomerular injury. This therapeutic strategy may
be more efficient for treatment or prevention of progressive chronic glomerular injury or sclerosis
compared with the approaches that just target the inflammatory pathways.
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• One of the top 10 Pre-Doctoral finalists in APS Renal Section Excellence in Renal Research
North Carolina Agricultural and Technical State University, Greensboro, NC 2011-2013
Master of Science in Biology
• Basic Immune Mechanisms Training Grant Pre-Doctoral Recipient
Fayetteville State University, Fayetteville, NC 2007-2011
Bachelor of Science in Biology, with honors
• 2010 Bronco McNair Scholar
• First place in FSU Innovative Curriculum Approach for Mathematics and Science (FICAMS) poster presentation
competition
• First place in FSU McNair Program and OpTIMUM Program Summer Research Internship Closing Ceremony oral
presentation competition

Research Experience
Doctoral Dissertation, Virginia Commonwealth University, Richmond, VA 2014-Present
Adviser: Dr. Pin-Lan Li
Role of Vav2 in Podocyte Inflammasome Activation and Glomerular Injury during Hyperhomocysteinemia
• Determining the early molecular mechanisms leading to the development of end-stage renal disease associated
with hyperhomocysteinemia.
Master’s Thesis, North Carolina Agricultural and Technical State University, Greensboro, NC 2011-2013
(Research Adviser: Dr. Elimelda M. Ongeri
Role of Meprins in the Pathogenesis of Diabetic Nephropathy
• Studied diabetic nephropathy in meprin deficient mice.
• Investigated the role of hypoxia inducible factors in acute kidney injury.
Undergraduate Ronald E. McNair Scholar, Fayetteville State University, Fayetteville, NC Summer 2010
Adviser: Dr. Shirley Chao
Impact of Pseudomonas aerguinosa on Reducing Toxicity of Diazinon in the Earthworm (Lumbricus terrestris) and
Mealworm (Tenebrio molitor)
• Investigated the toxicity of Diazinon in the environment of soil-dwelling organisms. Observed how bioremediation
reduces the effects of Diazinon on acetylcholinesterase in the nervous system.
FICAMS Undergraduate Researcher, Fayetteville State University, Fayetteville, NC 2008- 2009
Adviser: Dr. Stephen Salek
A Comparison of the Effectiveness of Traditional and Computer Simulated Biology Laboratory Exercises
• Used two methods of instruction to teach undergraduate non-biology majors about the anatomy and physiology of
the squid (Loligo pealei)
• Formatted a short lab practical using a dissected specimen.

Teaching Experience
Teaching Assistant, Biological Science Laboratory North Carolina Agricultural and Technical State University,
Fall 2011
• Taught laboratory section and provided support for faculty member in charge.
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Leadership Experience
Secretary, Virginia Commonwealth University Pharmacology and Toxicology Student Officer 2015-2016
• Responsibilities included maintaining detailed records of meetings and upcoming club events.
Graduate Student Mentor, Initiative for Maximizing Student Diversity Virginia Commonwealth University 2014Present
• Advised incoming undergraduate and graduate students about graduate school and VCU campus.
Community Outreach, Sunshine Committee Sandy Lane Church of Christ 2015-Present
• Served Richmond and surrounding area residents to provide personal care to the sick and support for bereaved
families.
Shift Leader, Quiznos Sub 2006-2011
• Directed team of employees in daily operations during night shift and interacted with customers to ensure a
satisfactory experience.
• Assisted in food prepping and marketed new promotions.
• Maintained a clean work environment.
•Trained newly hired personnel.

Technical Skills
• Maintenance of cell lines
• Gene manipulation by RNAinteference or nucleofection
• Protein purification by size exclusion chromatography
• Immunoprecipitation of complexes for identification by Western blot analysis
• Detection of proteins by Immunohistochemistry and biochemical assays such as ELISA
• Handling of mice
• Fluorescence and Confocal Microscopy imaging

Research Publications
Conley SM, Abais JM, Boini KM and Li PL. Inflammasome Activation in Chronic Glomerular Diseases. Current
Drug Targets. Accepted May 2016
Martin BL, Conley SM, Harris RS, Stanley CD, Niyitegeka JM and Ongeri EM. Hypoxia Associated Proteolytic
Processing of OS-9 by the Metalloproteinase Meprin β. Int J Nephrol. 2016: 2851803, 2016. PMCID: PMC4961814
Zhu Q, Li XX, Wang W, Hu J, Li PL, Conley SM and Li N. Mesenchymal stem cell transplantation inhibited high
salt-induced activation of the NLRP3 inflammasome in the renal medulla in Dahl S rats. Am J Physiol Renal
Physiol. 310: F621-F627, 2016. PMCID: PMC4824142
Xia M, Conley SM, Li G, Li PL and Boini KM. Inhibition of hyperhomocysteinemia-induced Inflammasome
activation and glomerular sclerosis by NLRP3 gene deletion. Cell Physiol and Biochem 34: 829-841, 2014. PMCID:
PMC4864609
Abais JM, Xia M, Li G, Chen Y, Conley SM, Gehr TW, Boini KM and Li PL. Nod-like receptor protein 3 (NLRP3)
Inflammasome activation and podocytes injury via thioredoxin-interacting protein (TXNIP) during
hyperhomocysteinemia. J Bio Chem. 289: 27159-27168, 2014. PMCID: PMC4175351

Professional Presentations
Conley S and Li N, Possible Role of the Renal Medullary Inflammasome in Salt Sensitivity Hypertension. Presented
November 18, 2013 at the First Laboratory Rotation Research Colloquium, Virginia Commonwealth University,
Richmond, VA.
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Selected Conference Presentations
Conley SM, Chen Z, Li G, Xia M, Boini KM, Gehr TW and Li PL, Role of Vav2 in Podocyte Inflammasome
Activation and Glomerular Injury during Hyperhomocysteinemia. Experimental Biology 2016, San Diego, CA.
Chen Z, Conley SM, Li G, Xia M, Gehr TW, Boini KM and Li PL, NLRP3 Inflammasome as a Novel Target for
Docosahexaenoic Acid and Its Metabolites to Abrogate Glomerular Injury during Hyperhomocysteinemia.
Experimental Biology 2016, San Diego, CA
Conley S, Han J, Hurley S and Ongeri EM, Meprin Deficient Mice Have a More Severe Form of Diabetic
Nephropathy. Experimental Biology 2013, Boston, MA.
Conley S, Martin B and Ongeri EM, Meprins Cleave OS-9 Present in Mouse Kidneys Subjected to Ischemia
Reperfusion Acute Kidney Injury. Experimental Biology 2013, Boston, MA.
Conley S and Chao S, Impact of Pseudomonas aerguinosa on Reducing Toxicity of Diazinon in the Mealworm
(Tenebrio molitor). Presented November 20, 2010 at the State of North Carolina Undergraduate and Creativity
Symposium (SNCURCS), Raleigh, NC.
Conley S and Chao S, Impact of Pseudomonas aerguinosa on Reducing Toxicity of Diazinon in the Mealworm
(Tenebrio molitor). Presented November 11, 2010 at ABRCMS (Annual Biomedical Research Conference for
Minority Students), Charlotte, NC.
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